[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539833":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":11,"centralContacts":51,"locations":57,"responsibleParty":265,"collaborators":11,"id":267,"slug":11,"hasResults":268,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":11,"eligibilityCriteria":271,"healthyVolunteers":268,"sex":272,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":11,"studyType":278,"phases":279,"briefSummary":281,"conditions":282,"keywords":288,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":310},{"fullName":5,"class":6},"Fate Therapeutics","INDUSTRY",[8,17,20,23,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Regimen A (Single dose with AMP)","EXPERIMENTAL",null,[13,14,15,16],"Drug: FT819","Drug: Fludarabine","Drug: Cyclophosphamide","Drug: Bendamustine",{"label":18,"type":10,"description":11,"interventionNames":19},"Regimen B (Single-dose without AMP, with background therapy)",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Regimen C (Two-dose with AMP)",[13,14,15,16],{"label":24,"type":10,"description":11,"interventionNames":25},"Regimen D (Two-dose without AMP, with background therapy)",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Regimen B1 (Single-dose without AMP, background therapy temporarily suspended)",[13],[30,35,41,47],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"DRUG","FT819","FT819 will be administered as intravenous (IV) infusion at planned dose levels.",[9,18,27,21,24],{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Fludarabine","Fludarabine will be administered as an IV infusion at planned dose levels.",[9,21],[40],"FLUDARA",{"type":31,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Cyclophosphamide","Cyclophosphamide will be administered as an IV infusion at planned dose levels.",[9,21],[46],"CYTOXAN",{"type":31,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"Bendamustine","Bendamustine will be administered as an IV infusion at planned dose levels.",[9,21],[52],{"name":53,"role":54,"phone":55,"phoneExt":11,"email":56},"Fate Clinical Trials","CONTACT","858-875-1800","clinicaltrials@fatetherapeutics.com",[58,71,80,89,98,107,117,126,136,146,156,165,175,185,195,205,215,225,236,247,256],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":11},"Wallace Rheumatic Center","RECRUITING","Beverly Hills","California","90210","United States",{"type":66,"coordinates":67},"Point",[68,69],-118.40036,34.07362,{"lat":69,"lon":68},{"facility":72,"status":60,"city":73,"state":62,"zip":74,"country":64,"cosmosGeoPoint":75,"geoPoint":79,"contacts":11},"Providence Medical Foundation","Fullerton","92835",{"type":66,"coordinates":76},[77,78],-117.92534,33.87029,{"lat":78,"lon":77},{"facility":81,"status":60,"city":82,"state":62,"zip":83,"country":64,"cosmosGeoPoint":84,"geoPoint":88,"contacts":11},"University of California Irvine","Irvine","92868",{"type":66,"coordinates":85},[86,87],-117.82311,33.66946,{"lat":87,"lon":86},{"facility":90,"status":60,"city":91,"state":62,"zip":92,"country":64,"cosmosGeoPoint":93,"geoPoint":97,"contacts":11},"Children's Hospital Los Angeles Division Of Rheumatology","Los Angeles","90027",{"type":66,"coordinates":94},[95,96],-118.24368,34.05223,{"lat":96,"lon":95},{"facility":99,"status":60,"city":100,"state":62,"zip":101,"country":64,"cosmosGeoPoint":102,"geoPoint":106,"contacts":11},"University of California San Francisco","San Francisco","94110",{"type":66,"coordinates":103},[104,105],-122.41942,37.77493,{"lat":105,"lon":104},{"facility":108,"status":60,"city":109,"state":110,"zip":111,"country":64,"cosmosGeoPoint":112,"geoPoint":116,"contacts":11},"University of Florida","Gainesville","Florida","32610",{"type":66,"coordinates":113},[114,115],-82.32483,29.65163,{"lat":115,"lon":114},{"facility":118,"status":60,"city":119,"state":110,"zip":120,"country":64,"cosmosGeoPoint":121,"geoPoint":125,"contacts":11},"Nicklaus Children's Hospital","Miami","33155",{"type":66,"coordinates":122},[123,124],-80.19366,25.77427,{"lat":124,"lon":123},{"facility":127,"status":60,"city":128,"state":129,"zip":130,"country":64,"cosmosGeoPoint":131,"geoPoint":135,"contacts":11},"University of Louisville","Louisville","Kentucky","40202",{"type":66,"coordinates":132},[133,134],-85.75941,38.25424,{"lat":134,"lon":133},{"facility":137,"status":60,"city":138,"state":139,"zip":140,"country":64,"cosmosGeoPoint":141,"geoPoint":145,"contacts":11},"University of Minnesota Medical School","Minneapolis","Minnesota","55455",{"type":66,"coordinates":142},[143,144],-93.26384,44.97997,{"lat":144,"lon":143},{"facility":147,"status":60,"city":148,"state":149,"zip":150,"country":64,"cosmosGeoPoint":151,"geoPoint":155,"contacts":11},"University of Nebraska Medical Center","Omaha","Nebraska","68198",{"type":66,"coordinates":152},[153,154],-95.94043,41.25626,{"lat":154,"lon":153},{"facility":157,"status":60,"city":158,"state":158,"zip":159,"country":64,"cosmosGeoPoint":160,"geoPoint":164,"contacts":11},"Montefiore Medical Center","New York","10467",{"type":66,"coordinates":161},[162,163],-74.00597,40.71427,{"lat":163,"lon":162},{"facility":166,"status":60,"city":167,"state":168,"zip":169,"country":64,"cosmosGeoPoint":170,"geoPoint":174,"contacts":11},"Duke University Health System","Durham","North Carolina","27705",{"type":66,"coordinates":171},[172,173],-78.89862,35.99403,{"lat":173,"lon":172},{"facility":176,"status":60,"city":177,"state":178,"zip":179,"country":64,"cosmosGeoPoint":180,"geoPoint":184,"contacts":11},"MetroHealth","Cleveland","Ohio","44109",{"type":66,"coordinates":181},[182,183],-81.69541,41.4995,{"lat":183,"lon":182},{"facility":186,"status":60,"city":187,"state":188,"zip":189,"country":64,"cosmosGeoPoint":190,"geoPoint":194,"contacts":11},"University of Oklahoma","Oklahoma City","Oklahoma","73019",{"type":66,"coordinates":191},[192,193],-97.51643,35.46756,{"lat":193,"lon":192},{"facility":196,"status":60,"city":197,"state":198,"zip":199,"country":64,"cosmosGeoPoint":200,"geoPoint":204,"contacts":11},"Jefferson Einstein Hospital Philadelphia","Philadelphia","Pennsylvania","19141",{"type":66,"coordinates":201},[202,203],-75.16362,39.95238,{"lat":203,"lon":202},{"facility":206,"status":60,"city":207,"state":208,"zip":209,"country":64,"cosmosGeoPoint":210,"geoPoint":214,"contacts":11},"Regional One Health","Memphis","Tennessee","38103",{"type":66,"coordinates":211},[212,213],-90.04898,35.14953,{"lat":213,"lon":212},{"facility":216,"status":60,"city":217,"state":11,"zip":218,"country":219,"cosmosGeoPoint":220,"geoPoint":224,"contacts":11},"Hôpital La Pitié Salpêtrière","Paris","75013","France",{"type":66,"coordinates":221},[222,223],2.3488,48.85341,{"lat":223,"lon":222},{"facility":226,"status":60,"city":227,"state":228,"zip":229,"country":230,"cosmosGeoPoint":231,"geoPoint":235,"contacts":11},"Uppsala University","Uppsala","Uppland","752 37","Sweden",{"type":66,"coordinates":232},[233,234],17.63889,59.85882,{"lat":234,"lon":233},{"facility":237,"status":60,"city":238,"state":239,"zip":240,"country":241,"cosmosGeoPoint":242,"geoPoint":246,"contacts":11},"Manchester University NHS Foundation Trust","Manchester","Greater Manchester","M139WL","United Kingdom",{"type":66,"coordinates":243},[244,245],-2.23743,53.48095,{"lat":245,"lon":244},{"facility":248,"status":60,"city":249,"state":11,"zip":250,"country":241,"cosmosGeoPoint":251,"geoPoint":255,"contacts":11},"Cambridge University Hospitals NHS Foundation Trust","Cambridge","CB2 0QQ",{"type":66,"coordinates":252},[253,254],0.11667,52.2,{"lat":254,"lon":253},{"facility":257,"status":60,"city":258,"state":11,"zip":259,"country":241,"cosmosGeoPoint":260,"geoPoint":264,"contacts":11},"University College of London Hospitals NHS Trust (UCLH)","London","NW1 2PQ",{"type":66,"coordinates":261},[262,263],-0.12574,51.50853,{"lat":263,"lon":262},{"type":266,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100539833",false,"NCT06308978","A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","Key Inclusion Criteria:\n\n* Age: 12 to 70 years old.\n* Diagnosis: Must have active B-cell mediated autoimmune disease (SLE, AAV, IIM, or SSc) confirmed by standard criteria.\n* Disease Severity: Moderate to severe, requiring at least two prior treatments that were ineffective.\n* Health Status: Adequate organ function to tolerate treatment.\n* Consent: Able to provide informed consent or assent\u002Fobtain parental consent and comply with study procedures.\n\nKey Exclusion Criteria:\n\n* Pregnancy\u002FBreastfeeding: Women must not be pregnant or nursing.\n* Severe Organ Dysfunction: Significant heart, lung, liver, or kidney impairment.\n* Active Infections: No recent or ongoing serious infections.\n* Recent Cancer or Prior Cell Therapy: No active\u002Frecent malignancies, prior CAR T-cell therapy, or organ transplant.\n* Allergies: No known allergies to study treatments.\n* Weight Restriction: Must weigh at least 50 kg (110 lbs).","ALL","12 Years","70 Years",{"count":276,"type":277},244,"ESTIMATED","INTERVENTIONAL",[280],"PHASE1","This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.",[283,284,285,286,287],"Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)","Idiopathic Inflammatory Myositis (IIM)","Systemic Sclerosis (SSc)","Systemic Lupus Erythematosus (SLE)","Lupus Nephritis",[32,5,289,290,291,292,293,294,295,296,297,298,299,300,287],"Idiopathic inflammatory myositis (IIM)","Systemic lupus erythematosus (SLE)","Systemic sclerosis (SSc)","Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV)","Allogeneic CAR-T","CD19-Targeted Therapy","Cell Therapy for Autoimmune Diseases","B-Cell Depletion in Autoimmune Disease","Phase 1 Clinical Trial","Allogeneic CAR cells","Autoimmune Diseases","A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases","2026-05-19",{"date":303,"type":304},"2026-05-22","ACTUAL",{"date":306,"type":304},"2024-03-28",{"date":308,"type":277},"2042-09-30",{"name":5,"class":6},21]